MOLOGEN AG
MOLOGEN AG: Aarhus University Hospital initiates MGN1703 study in HIV patients
DGAP-News: MOLOGEN AG / Key word(s): Study 2015-05-08 / 08:35 --------------------------------------------------------------------- PRESS RELEASE N° 06 / 2015 of 05/08/2015 MOLOGEN AG: Aarhus University Hospital initiates MGN1703 study in HIV patients Berlin, May 8, 2015 - The biotechnology company MOLOGEN AG announced today that it has entered into a collaboration agreement with the Danish Aarhus University Hospital. The agreement relates to an early stage trial with MOLOGEN's immunomodulator MGN1703 in HIV (Human Immunodeficiency Virus) patients. This is the first time that MGN1703 is evaluated in patients with diseases other than cancer. Thus the potential range of applications of the product could be expanded. "MGN1703 is a TLR9 agonist with an excellent safety profile and has demonstrated its efficacy in various trials. We want to find out whether the broad immune activation induced in patients with cancer is also beneficial to patients with HIV", said Ole Schmeltz Søgaard, MD, PhD, Associate Professor at the Aarhus University Hospital, Dept. of Infectious Diseases, Aarhus, Denmark. The aim of the so-called TEACH study is to see if the immunotherapy with MGN1703 can activate the innate and adaptive immune system in HIV patients, to enhance killing of the HIV infected cells. Aarhus University Hospital will conduct the trial in two hospital centers in Denmark and already received respective funding from the American Foundation for AIDS research (amfAR). MOLOGEN will provide the immunomodulator MGN1703. The study is planned to start within the next few weeks. MGN1703 is currently being investigated in the registration trial IMPALA in colorectal cancer and in the randomized trial IMPULSE in small cell lung cancer. Both studies are currently enrolling patients. About TEACH TEACH (Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV infection) is a non-randomized interventional phase I/IIa trial of MGN1703 in HIV-infected patients. Participants will receive four weeks of MGN1703 therapy (60 mg s.c. twice weekly). During these four weeks, each participant will be closely monitored for the safety and therapeutic effects of the drug. 14-16 patients will participate in two study centers in Denmark. The primary endpoint of the study is the change in proportions of activated natural killer cells in the patients. Secondary study endpoints include, among others, a collection of safety, virological, immunological and pharmacodynamic data. HIV infects the immune system and destroys or affects the proper function of immune cells. Without antiretroviral treatment this eventually leads to immune deficiency and the immune system can no longer fight off a wide range of infections and diseases. HIV remains a serious worldwide health issue. According to estimates by WHO and UNAIDS (United Nations Programme on AIDS) 35 million people worldwide were living with HIV at the end of 2013. Some 2.1 million people became newly infected in that same year, and 1.5 million died as a result of HIV-related causes globally. About MGN1703 MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN that broadly activates the immune system. This activation can be utilized to enable the immune system to increase the recognition and combat of cancer cells. Due to this mechanism of action, it is predicted that MGN1703 can be applied to a number of diseases. MOLOGEN AG MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immune therapies and DNA vaccines against infectious diseases. The cancer immune therapy MGN1703 is the company's lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. For more information on the trials please visit www.clinicaltrials.gov. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation. --------------------------------------------------------------------- 2015-05-08 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 354781 2015-05-08
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden